48,851
edits
Difference between revisions of "C-cell hyperplasia"
Jump to navigation
Jump to search
→Gross
(→Gross) |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 13: | Line 13: | ||
| Molecular = | | Molecular = | ||
| IF = | | IF = | ||
| Gross = not apparent | | Gross = not apparent; mid portion of lobe to upper third of lobe | ||
| Grossing = | | Grossing = | ||
| Site = [[thyroid gland]] | | Site = [[thyroid gland]] | ||
| Assdx = | | Assdx = | ||
| Syndromes = [[Multiple endocrine neoplasia type 2A]] | | Syndromes = [[Multiple endocrine neoplasia type 2A]], [[Multiple endocrine neoplasia type 2B]] | ||
| Clinicalhx = | | Clinicalhx = +/-family history of thyroid cancer or MEN 2A or MEN 2B | ||
| Signs = | | Signs = +/-marfanoid habitus (seen in MEN 2B) | ||
| Symptoms = | | Symptoms = | ||
| Prevalence = uncommon | | Prevalence = uncommon | ||
| Line 27: | Line 27: | ||
| Prognosis = benign in itself | | Prognosis = benign in itself | ||
| Other = | | Other = | ||
| ClinDDx = | | ClinDDx = | ||
| Tx = prophylatic surgery | | Tx = prophylatic surgery | ||
}} | }} | ||
| Line 40: | Line 40: | ||
==Gross== | ==Gross== | ||
*Not visible. | *Not visible on gross. | ||
Location:<ref>URL: [http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/Thyroid_11protocol.pdf http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/Thyroid_11protocol.pdf]. Accessed on: 7 April 2012.</ref> | |||
*Mid portion of lobe to upper third of lobe. | |||
**Not at the poles. | |||
**Not in the isthmus. | |||
==Microscopic== | ==Microscopic== | ||
Features: | Features: | ||
*Definitions vary.<ref>Raphael S. 17 January 2011.</ref> | *Definitions vary.<ref>Raphael S. 17 January 2011.</ref> | ||
**One definition - either of the following:<ref name=pmid19726541>{{cite journal |author=Machens A, Hoffmann F, Sekulla C, Dralle H |title=Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer |journal=Endocr. Relat. Cancer |volume=16 |issue=4 |pages=1291–8 |year=2009 |month=December |pmid=19726541 |doi=10.1677/ERC-09-0136 |url=http://erc.endocrinology-journals.org/cgi/content/full/16/4/1291}}</ref> | **One definition - either of the following:<ref name=pmid19726541>{{cite journal |author=Machens A, Hoffmann F, Sekulla C, Dralle H |title=Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer |journal=Endocr. Relat. Cancer |volume=16 |issue=4 |pages=1291–8 |year=2009 |month=December |pmid=19726541 |doi=10.1677/ERC-09-0136 |url=http://erc.endocrinology-journals.org/cgi/content/full/16/4/1291}}</ref> | ||
| Line 90: | Line 91: | ||
==IHC== | ==IHC== | ||
*Chromogranin A +ve. | *Chromogranin A +ve. | ||
*CEA +ve. | *[[CEA]] +ve. | ||
*Synaptophysin +ve. | *Synaptophysin +ve. | ||